跳至主要内容
临床试验/CTRI/2024/02/062389
CTRI/2024/02/062389尚未招募不适用

Effectiveness and Safety of Amlodipine and Telmisartan in Treatment Naïve Hypertension: An EMR-based Retrospective, Comparative Study

Dr Reddys Laboratories Ltd1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2024年2月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
2,000
试验地点
1
主要终点
Change in SBP and DBP from baseline to 12 weeks.

研究概览

简要总结

While Amlodipine and Telmisartan are widely used antihypertensive drugs, there is a lack of head to head comparative studies in newly diagnosed hypertensive patients. There is a need for comparative studies to determine which drug is more effective and safer for naïve patient population.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Treatment-naïve patients with essential or primary hypertension.
  • Patients who were prescribed amlodipine or telmisartan monotherapy as first line therapy.

排除标准

  • Patients with secondary hypertension.
  • Patients prescribed with any other antihypertensive drug Patients prescribed with any combination of antihypertensive drugs.

结局指标

主要结局

Change in SBP and DBP from baseline to 12 weeks.

时间窗: An interim visit of 2 weeks and a final visit of 12 weeks will be considered for analysis.

次要结局

  • Change in heart rate and assessment of pedal edema(Baseline to 2, and 12 weeks.)

研究者

申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Sagar Katare

Dr Reddys Laboratories Limited

研究点 (1)

Loading locations...

相似试验